Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2021-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Norway, about 60% of all children with cerebral palsy (CP) are being treated with botulinum toxin A (BoNT-A) at 6 years of age, mainly in the legs. Despite this widespread use of the drug, the evidence for a positive effect on walking is insufficient. Moreover, large variation in effect is seen by clinicians. The main objective of the present study is to investigate whether injections with BoNT-A in the calf muscles make walking easier in children with spastic CP within 6 months, reflected by reduced energy cost during walking.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy

NCT00549471

Cerebral Palsy

TERMINATED PHASE4

Effect of Botulinum Toxin on Muscles of Children With Cerebral Palsy

NCT02853240

Cerebral Palsy

COMPLETED NA

The Effect of Botox on Children With Cerebral Palsy

NCT00503620

Cerebral Palsy

COMPLETED

Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy

NCT01276015

Cerebral Palsy and Botulinum Toxin

COMPLETED PHASE4

Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy

NCT00432055

Cerebral Palsy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an industry independent multicentre clinical trial. The randomization will be done by a computer number random generator and will be carried out and held by the unit of Applied Clinical Research at NTNU. Two strata: age and center.

The study will be conducted according to Consort guidelines and guidelines for Good Clinical Practice. It is approved by the local Ethical committee (REK Nord) and the Norwegian Drug Agency.

Primary research question is: Do BoNT-A injections in the calf muscles make walking easier in children with CP? Secondary research questions: 1) Do BoNT-A injections in the calf muscles increase activity? 2) Do BoNT-A injections in the calf muscles improve walking capacity 3) Do BoNT-A injections in the calf muscles improve perceived performance and satisfaction related to mobility tasks and 4) Do BoNT-A injections in the calf muscles reduce recurrent musculoskeletal pain? The participants will receive the treatment with both local anaesthesia and conscious sedation with oral or nasal benzodiazepines.Outcome measures are made at baseline and 4, 12 and 24 weeks after treatment, with primary endpoint at 12 weeks.

Data will be analyzed using a linear mixed model (LMM). The difference in change in the primary outcome measure (energy cost during walking) between the treated and placebo groups will be done using a post hoc test following the LMM. Secondary, the same model will be used to test for an effect also at 4 and 24 weeks post injection. Age, GMFCS Level, number of prior BoNT-A treatments and study center will be considered as potential covariates.

A substudy will be conducted within the frames of this RCT, aiming to identify characteristics of those who respond to the treatment compared to those who do not respond (outcome measures 6, 7,8 and 9).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Palsy Muscle Spasticity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

botox

Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.

Group Type EXPERIMENTAL

botox

Intervention Type DRUG

The agent will be given only once at point zero in the time scheme for the project.

placebo

Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

The agent will be given only once at point zero in the time scheme for the project.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

botox

The agent will be given only once at point zero in the time scheme for the project.

Intervention Type DRUG

placebo

The agent will be given only once at point zero in the time scheme for the project.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

botulinum toxin A sodium chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with unilateral or bilateral CP
* GMFCS level I and II
* Signed informed consent
* expected cooperation of the patients for the treatment and follow up.

Exclusion Criteria

* BoNT-A injections in the lower legs in the last 6 months before intervention
* history of adverse reactions to BoNT-A
* Known hypersensitivity to BoNT-A or to any of the excipients
* Orthopedic surgery in the legs in the last 2 years
* Major cognitive impairments (must be able to take verbal instructions and conduct the test procedure)
* infection at the proposed injection site(s)
* Subclinical or clinical evidence of defective neuromuscular transmission e.g. myasthenia gravis or Lambert-Eaton Syndrome in patients with peripheral motor neuropathic diseases (e.g. amyotrophic lateral sclerosis or motor neuropathy)
* other underlying neurological disorders that may be affected by BoNT-A injections
* Use of aminoglycoside antibiotics or spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking agents)
* Pregnant or breast-feeding
* Childbearing potential not using contraception
* any reason why, in the opinion of the investigator, the patient should not participate
* Children needing deep sedation under treatment

Minimum Eligible Age

4 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No